CareDx (CDNA) Insider Hannah Valantine Sells $280K of Stock

On June 15, 2026, Hannah Valantine sold 12,103 shares of CDNA in a planned transaction. The shares were sold at an average price of $23.11, bringing the total value of the sale to approximately $279,700. This sale was part of a pre-arranged trading plan.

Other Institutional Activity in CDNA

Several institutional investors also made moves in CDNA recently. BlackRock, Inc. reduced its holdings by 128,313 shares, ending with 4,522,096 shares valued at about $78.5 million. Meanwhile, BAMCO Inc. increased its position by 181,229 shares, holding 3,336,409 shares worth approximately $57.9 million. State Street Corp added 22,633 shares, bringing its total to 2,760,385 shares valued at $47.9 million. ARK Investment Management LLC increased its stake by 91,153 shares, now holding 2,227,556 shares valued at around $38.7 million. Braidwell LP made a notable increase of 587,926 shares, resulting in 2,173,146 shares worth about $37.7 million.

CareDx, Inc. Stock Down 63.9%

Shares of CDNA traded near $24.08. The stock has experienced a range over the past 52 weeks, with a low of $19.00 and a high of $28.50. Investors are watching how the stock performs amid these insider and institutional activities.

Insider Buying and Selling at CareDx, Inc.

In addition to Hannah Valantine's planned sale, several insiders were involved in transactions around the same period. On June 12, 2026, Christine Cournoyer, Suresh Gunasekaran, Fred Cohen, and George Bickerstaff each purchased 9,795 shares. These transactions were not planned, contrasting with Valantine's planned sale.

Analysts Set New Price Targets

Analysts have been active in setting price targets for CDNA. On April 29, 2026, BTIG maintained its 'buy' rating with a price target of $28. Earlier in February, BTIG also maintained a 'buy' rating with a $26 target. Wells Fargo, on February 25, 2026, maintained a 'hold' rating with a $21 target. The consensus among analysts suggests a mixed outlook, with a range of price targets reflecting varying expectations.

Bottom Line

Hannah Valantine's recent planned sale of CDNA shares highlights ongoing insider activity, which investors often track for insights into company sentiment. Institutional investors have also adjusted their holdings, reflecting diverse strategies. While the stock's performance continues to be monitored, analysts' mixed ratings and targets suggest varied opinions on its future trajectory.